Akero Therapeutics Financials
This page shows Akero Therapeutics (AKRO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Akero Therapeutics passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Akero Therapeutics generates $0.91 in operating cash flow (-$230.1M OCF vs -$252.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Akero Therapeutics earns $-61.1 in operating income for every $1 of interest expense (-$285.4M vs $4.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Akero Therapeutics's EBITDA was -$285.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 147.9% from the prior year.
Akero Therapeutics reported -$252.1M in net income in fiscal year 2025. This represents a decrease of 125.0% from the prior year.
Akero Therapeutics earned $-3.75 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 30.7% from the prior year.
Cash & Balance Sheet
Akero Therapeutics held $340.2M in cash against $0 in long-term debt as of fiscal year 2025.
Akero Therapeutics paid $0.00 per share in dividends in fiscal year 2025.
Akero Therapeutics had 80M shares outstanding in fiscal year 2025. This represents an increase of 69.9% from the prior year.
Margins & Returns
Akero Therapeutics's ROE was -33.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.7 percentage points from the prior year.
Capital Allocation
Akero Therapeutics invested $247.5M in research and development in fiscal year 2025. This represents an increase of 190.2% from the prior year.
AKRO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $78.9M+13.9% | $69.3M-0.4% | $69.6M | N/A | $72.2M+30.6% | $55.3M+9.2% | $50.6M | N/A |
| SG&A Expenses | $11.4M-2.3% | $11.6M+2.7% | $11.3M | N/A | $9.5M-9.1% | $10.4M+12.0% | $9.3M | N/A |
| Operating Income | -$90.2M-11.6% | -$80.9M0.0% | -$80.9M | N/A | -$81.7M-24.3% | -$65.7M-9.7% | -$60.0M | N/A |
| Interest Expense | $1.1M-6.8% | $1.2M+1.6% | $1.2M | N/A | $1.2M+1.2% | $1.2M+24.2% | $991K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$81.6M-15.7% | -$70.5M+0.3% | -$70.7M | N/A | -$72.7M-29.9% | -$56.0M-5.0% | -$53.3M | N/A |
| EPS (Diluted) | $-0.99-15.1% | $-0.86+4.4% | $-0.90 | N/A | $-1.05-29.6% | $-0.81+10.0% | $-0.90 | N/A |
AKRO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0B-9.3% | $1.1B-4.0% | $1.2B+40.0% | $825.9M+1.0% | $817.5M-5.5% | $865.0M-5.2% | $912.2M+57.2% | $580.3M |
| Current Assets | $754.5M-1.3% | $764.6M+7.2% | $713.2M-7.4% | $770.4M+3.1% | $746.9M-3.8% | $776.0M-14.8% | $911.3M+62.7% | $560.0M |
| Cash & Equivalents | $176.0M-20.1% | $220.4M+18.6% | $185.9M-45.4% | $340.2M+7.6% | $316.1M+1.8% | $310.4M-50.3% | $623.9M+166.4% | $234.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $47.9M-42.5% | $83.3M+15.7% | $72.0M-5.0% | $75.8M-4.4% | $79.2M+18.3% | $67.0M+1.5% | $66.0M+46.8% | $45.0M |
| Current Liabilities | $47.7M-21.1% | $60.4M+42.3% | $42.4M+6.8% | $39.8M-8.2% | $43.3M+38.9% | $31.2M+3.0% | $30.3M+58.2% | $19.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $957.6M-6.6% | $1.0B-5.4% | $1.1B+44.5% | $750.1M+1.6% | $738.3M-7.5% | $798.1M-5.7% | $846.3M+58.1% | $535.3M |
| Retained Earnings | -$1.0B-8.4% | -$967.4M-7.9% | -$896.9M-8.6% | -$826.2M-9.3% | -$756.1M-10.6% | -$683.4M-8.9% | -$627.4M-9.3% | -$574.1M |
AKRO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$67.2M-39.2% | -$48.2M+28.7% | -$67.7M-0.9% | -$67.1M+4.7% | -$70.4M-22.6% | -$57.5M-63.5% | -$35.1M+27.7% | -$48.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $56.8M-28.4% | $79.3M+116.5% | -$482.2M-3257.3% | $15.3M-79.1% | $73.1M+128.6% | -$255.9M-542.4% | $57.8M+352.4% | $12.8M |
| Financing Cash Flow | -$34.0M-1091.2% | $3.4M-99.1% | $395.5M+420.5% | $76.0M+2377.7% | $3.1M+2144.7% | -$150K-100.0% | $366.9M+72995.2% | $502K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AKRO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -8.5%-1.7pp | -6.9%-0.3pp | -6.5% | N/A | -9.8%-2.8pp | -7.0%-0.7pp | -6.3% | N/A |
| Return on Assets | -8.1%-1.8pp | -6.4%-0.2pp | -6.1% | N/A | -8.9%-2.4pp | -6.5%-0.6pp | -5.9% | N/A |
| Current Ratio | 15.83+3.2 | 12.66-4.1 | 16.80-2.6 | 19.38+2.1 | 17.25-7.6 | 24.89-5.2 | 30.12+0.8 | 29.27 |
| Debt-to-Equity | 0.05-0.0 | 0.08+0.0 | 0.07-0.0 | 0.100.0 | 0.11+0.0 | 0.080.0 | 0.080.0 | 0.08 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Akero Therapeutics profitable?
No, Akero Therapeutics (AKRO) reported a net income of -$252.1M in fiscal year 2025.
What is Akero Therapeutics's EBITDA?
Akero Therapeutics (AKRO) had EBITDA of -$285.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Akero Therapeutics's return on equity (ROE)?
Akero Therapeutics (AKRO) has a return on equity of -33.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Akero Therapeutics's operating cash flow?
Akero Therapeutics (AKRO) generated -$230.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Akero Therapeutics's total assets?
Akero Therapeutics (AKRO) had $825.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Akero Therapeutics spend on research and development?
Akero Therapeutics (AKRO) invested $247.5M in research and development during fiscal year 2025.
What is Akero Therapeutics's current ratio?
Akero Therapeutics (AKRO) had a current ratio of 19.38 as of fiscal year 2025, which is generally considered healthy.
What is Akero Therapeutics's debt-to-equity ratio?
Akero Therapeutics (AKRO) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Akero Therapeutics's return on assets (ROA)?
Akero Therapeutics (AKRO) had a return on assets of -30.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Akero Therapeutics's cash runway?
Based on fiscal year 2025 data, Akero Therapeutics (AKRO) had $340.2M in cash against an annual operating cash burn of $230.1M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Akero Therapeutics's Piotroski F-Score?
Akero Therapeutics (AKRO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Akero Therapeutics's earnings high quality?
Akero Therapeutics (AKRO) has an earnings quality ratio of 0.91x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Akero Therapeutics cover its interest payments?
Akero Therapeutics (AKRO) has an interest coverage ratio of -61.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.